My bookmarksSign up free
Source

Commission Delegated Regulation (EU) 2022/315 of 17 December 2021 amending Delegated Regulation (EU) 2016/161 as regards the derogation from the obligation of wholesalers to decommission the unique identifier of medicinal products exported to the United Kingdom (Text with EEA relevance)

Commission Delegated Regulation (EU) 2022/315 of 17 December 2021 amending Delegated Regulation (EU) 2016/161 as regards the derogation from the obligation of wholesalers to decommission the unique identifier of medicinal products exported to the United Kingdom (Text with EEA relevance)

Delegated Regulation (EU) 2022/315 · Regulation · 2 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Verification of the authenticity of the unique identifier by wholesalers

Article 1

Open ↗

Delegated Regulation (EU) 2016/161 is amended as follows: (1) in Article 3(2), point (d) is replaced by the following: ‘(d) ‘active unique identifier’ means a unique identifier which has not been decommissioned or which is no longer decommissioned, and which has not been identified as a ‘non-Union pack’ as referred to in Article 36, point (p);’ (2) Article 20 is replaced by the following: ‘Article 20 Verification of the authenticity of the unique identifier by wholesalers A wholesaler shall verify the authenticity of the unique identifier of at least the following medicinal products in his physical possession: (a) medicinal products returned to him by persons authorised or entitled to supply medicinal products to the public or by another wholesaler; (b) medicinal products he receives from a wholesaler who is neither the manufacturer nor the wholesaler holding the marketing authorisation nor a wholesaler who is designated by the marketing authorisation holder, by means of a written contract, to store and distribute the products covered by his marketing authorisation on his behalf. A wholesaler established in Northern Ireland, Cyprus, Ireland or Malta shall perform adequate verifications to ensure that shipments of medicinal products manufactured and labelled for the United Kingdom market comply with the requirement to bear safety features under Article 54a(1) of Directive 2001/83/EC when received from the manufacturer, the marketing authorisation holder or a wholesaler who is designated by the marketing authorisation holder, by means of a written contract, to store and distribute the products covered by his marketing authorisation on his behalf.’ (3) in Article 22, the final paragraph is replaced by the following: ‘By way of derogation from point (a), until 31 December 2024, the obligation to decommission the unique identifier of medicinal products which the wholesaler intends to distribute outside of the Union shall not apply to medicinal products manufactured and labelled for the United Kingdom market or for the United Kingdom market and the markets of Cyprus, Ireland or Malta, which he intends to distribute in the United Kingdom.’ (4) in Article 26, the following paragraph 4 is added: ‘4.   Until 31 December 2024, the authorities of the United Kingdom in respect of Northern Ireland may waive the obligation to verify the safety features and decommission the unique identifier of a medicinal product supplied to the persons or institutions listed in Article 23 for products for the market of the United Kingdom in respect of Northern Ireland supplied from wholesalers located in other parts of the United Kingdom.’ (5) in Article 32(1), point (b), a final sentence is added: ‘Repositories which serve territories outside of the Union shall not be connected to the hub.’ (6) in Article 36, the following point (p) is added: ‘(p) the triggering of an alert identified as a ‘non-Union pack’ in the repositories system and in the terminal where the verification of the authenticity of a unique identifier in accordance with Article 11 takes place when both of the following conditions are met: (i) the verification finds that the medicinal product bearing the unique identifier is manufactured and labelled for the United Kingdom market or for the United Kingdom market and the markets of Cyprus, Ireland or Malta; (ii) the verification does not take place in Northern Ireland, Cyprus, Ireland or Malta.’

Article 2

Open ↗

This Regulation shall enter into force on the day following that of its publication in the Official Journal of the European Union . It shall apply from 1 January 2022.

Other acts of the same type
Commission Implementing Regulation (EU) 2021/1343 of 10 August 2021 approving amendments to the specification for a spirit drink whose name is registered as a geographical indication [Újfehértói meggypálinka]Commission Implementing Regulation (EU) 2021/1318 of 9 August 2021 correcting Implementing Regulation (EU) 2017/2470 establishing the Union list of novel foods, Decision 2008/968/EC authorising the placing on the market of arachidonic acid-rich oil from Mortierella alpina as a novel food ingredient and Implementing Regulation (EU) 2020/484 authorising the placing on the market of lacto-N-tetraose as a novel food (Text with EEA relevance)Commission Implementing Regulation (EU) 2021/1319 of 9 August 2021 authorising changes in the specifications of the novel food Coriander seed oil from Coriandrum sativum and amending Implementing Regulation (EU) 2017/2470 (Text with EEA relevance)Commission Implementing Regulation (EU) 2021/1310 of 6 August 2021 correcting certain language versions of Regulation (EU) No 1178/2011 laying down technical requirements and administrative procedures related to civil aviation aircrew pursuant to Regulation (EC) No 216/2008 of the European Parliament and of the Council (Text with EEA relevance)Commission Implementing Regulation (EU) 2021/1354 of 6 August 2021 laying down technical information for the calculation of technical provisions and basic own funds for reporting with reference dates from 30 June 2021 until 29 September 2021 in accordance with Directive 2009/138/EC of the European Parliament and of the Council on the taking-up and pursuit of the business of Insurance and Reinsurance (Text with EEA relevance)Commission Implementing Regulation (EU) 2021/1367 of 6 August 2021 concerning the classification of certain goods in the Combined NomenclatureCommission Implementing Regulation (EU) 2021/1368 of 6 August 2021 concerning the classification of certain goods in the Combined NomenclatureCommission Implementing Regulation (EU) 2021/1369 of 6 August 2021 concerning the classification of certain goods in the Combined NomenclatureCommission Implementing Regulation (EU) 2021/1370 of 6 August 2021 concerning the classification of certain goods in the Combined NomenclatureCommission Delegated Regulation (EU) 2021/2003 of 6 August 2021 supplementing Directive (EU) 2018/2001 of the European Parliament and of the Council by establishing the Union renewable development platform (Text with EEA relevance)Commission Delegated Regulation (EU) 2021/2153 of 6 August 2021 supplementing Directive (EU) 2019/2034 of the European Parliament and of the Council with regard to regulatory technical standards specifying the criteria for subjecting certain investment firms to the requirements of Regulation (EU) No 575/2013 (Text with EEA relevance)Council Implementing Regulation (EU) 2021/1300 of 5 August 2021 implementing Regulation (EU) 2017/1509 concerning restrictive measures against the Democratic People’s Republic of Korea

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

Contents

What to look at next